Companies warned for selling unapproved opioid cessation products using deceptive claims

26 Jan 2018

The companies have 15 days to respond to the FDA and FTC.

FDA and the Federal Trade Commission (FTC) have posted joint warning letters to the marketers and distributors of 12 opioid cessation products, for illegally marketing unapproved products with claims about their ability to help in the treatment of opioid addiction and withdrawal.

Companies warned for selling unapproved opioid cessation products using deceptive claims

Health fraud scams like these can pose serious health risks. These products have not been demonstrated to be safe or effective and may keep some patients from seeking appropriate, FDA-approved therapies. Selling these unapproved products with claims that they can treat opioid addiction and withdrawal is a violation of the Federal Food, Drug, and Cosmetic Act. Making unsubstantiated therapeutic claims is also a violation of the Federal Trade Commission Act, which prohibits deceptive advertising.

The FDA and FTC issued joint warning letters to 11 companies for their products:

  • Opiate Freedom Center (“Opiate Freedom 5-Pack”)
  • U4Life, LLC (“Mitadone”)
  • CalmSupport, LLC (“CalmSupport”)
  • TaperAid (“TaperAid” & “TaperAid Complete”)
  • Medicus Holistic Alternatives LLC (“Natracet”)
  • NutraCore Health Products, LLC (“Opiate Detox Pro”)
  • Healthy Healing, LLC (“Withdrawal Support”)
  • Soothedrawal, Inc. (“Soothedrawal”)
  • Choice Detox Center, Inc. (“Nofeel”)
  • GUNA, Inc. (“GUNA-ADDICT 1”)
  • King Bio, Inc. (“AddictaPlex”).
  • The FTC sent four additional warning letters to other marketers of opioid cessation products.

    The FDA and FTC have requested responses from each of the companies within 15 working days. The companies are directed to inform each agency of the specific actions taken to address each agency’s concerns. The warning letters also state that failure to correct violations may result in law enforcement action such as seizure or injunction.

    Read More

    Related news

    New portable and ready-to-use upper respiratory drug delivery solution

    New portable and ready-to-use upper respiratory drug delivery solution

    11 Oct 2018

    PureHale is valuable to pharmaceutical partners seeking a system that can carry a range of formulations and comes in various container sizes.

    Read more 
    CPhI Worldwide announces the winners  of the 15th Pharma Awards

    CPhI Worldwide announces the winners of the 15th Pharma Awards

    10 Oct 2018

    17 winners chosen from over 250 entries, with Nanobiotix winning both ‘CEO‘ and ‘Pharma Company of the Year’ categories.

    Read more 
    CMOs to benefit from double digit approvals for ADCs in the next 3 years

    CMOs to benefit from double digit approvals for ADCs in the next 3 years

    9 Oct 2018

    Therapeutic ADC market expected to reach $4 billion by 2023.

    Read more 
    Micro-Sphere increases capsule filling capacity

    Micro-Sphere increases capsule filling capacity

    8 Oct 2018

    The MG2 Tekna increases the CDMO’s manufacturing capacity to up to 500 million capsules per year.

    Read more 
    Symbiosis secures FDA viral vector process approval

    Symbiosis secures FDA viral vector process approval

    5 Oct 2018

    Strengthens the CDMO's position as a centre of excellence as part of the viral vector drug development supply chain.

    Read more 
    Three-way collaboration to advance gene therapy

    Three-way collaboration to advance gene therapy

    4 Oct 2018

    Partnership aims to increase the robustness and reduce costs for the manufacturing of AAV vectors.

    Read more 
    New horizontal flow wrapping machine for hermetic packages

    New horizontal flow wrapping machine for hermetic packages

    3 Oct 2018

    Greater product protection thanks to reliable sealing technologies.

    Read more 
    Movement on the market reflected at CPhI Worldwide 2018

    Movement on the market reflected at CPhI Worldwide 2018

    3 Oct 2018

    Companies new to CPhI to showcase an exciting range of products and services ranging from electroceuticals to refrigerant alternatives.

    Read more 
    Niche CDMO confirms spray drying for highly potent drugs

    Niche CDMO confirms spray drying for highly potent drugs

    1 Oct 2018

    Idifarma's GMP spray drying technology for highly potent drugs up to Category 4 OEL/OEB is now operational.

    Read more 
    Custom scalable turnkey PODs for flexible continuous bioprocess and viral vector facility solutions

    Custom scalable turnkey PODs for flexible continuous bioprocess and viral vector facility solutions

    1 Oct 2018

    The PODs ease verification, qualification and validation challenges, and their flexibility allows them to support multiple products.

    Read more